Abnormal peri-organ or intra-organ fat (APIFat) Deposition: An underestimated predictor of vascular risk?

Current Vascular Pharmacology

Volumn 14, Issue 5, 2016, Pages 432-441

  Katsiki, Niki ^a   Athyros, Vasilios G ^a   Mikhailidis, Dimitri P ^b  

^a ARISTOTLE UNIVERSITY MEDICAL SCHOOL   (Greece)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Epicardial fat; Intramuscular fat; Non alcoholic fatty liver disease; Peripancreatic fat; Perirenal fat; Perivascular; Vascular risk

Indexed keywords

EZETIMIBE; GLITAZONE DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEPTIN; LIOTHYRONINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RESISTIN; ROSIGLITAZONE; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL;

ADIPOSE TISSUE; ARTERIAL STIFFNESS; ARTERIAL WALL THICKNESS; ARTICLE; BROWN ADIPOCYTE; CARDIOMETABOLIC RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMPUTER ASSISTED TOMOGRAPHY; DUAL ENERGY X RAY ABSORPTIOMETRY; EPICARDIAL FAT; FLOW-MEDIATED DILATION TEST; FRAMINGHAM RISK SCORE; GLUCOSE METABOLISM; HUMAN; INTRA ORGAN FAT; INTRA-ABDOMINAL FAT; INTRAMUSCULAR FAT; ISCHEMIC HEART DISEASE; LIPID METABOLISM; LIPID STORAGE; MICROALBUMINURIA; NEUTROPHIL LYMPHOCYTE RATIO; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONALCOHOLIC STEATOHEPATITIS; OBESITY; PERCUTANEOUS CORONARY INTERVENTION; PERI ORGAN FAT; PERICARDIAL FAT; PERIPANCREATIC FAT; PERIRENAL FAT; PERIVASCULAR ADIPOSE TISSUE; PLATELET LYMPHOCYTE RATIO; SEX DIFFERENCE; SUBCUTANEOUS FAT; WHITE ADIPOCYTE; ANIMAL; CARDIOVASCULAR DISEASES; COMPLICATION; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR;

ADIPOSE TISSUE; ADIPOSITY; ANIMALS; CARDIOVASCULAR DISEASES; HUMANS; OBESITY; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS;

EID: 85010880320     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/1570161114666160722112738     Document Type: Article

References (192)

1. Dempersmier J, Sul HS. Shades of brown: a model for thermogenic fat. Front Endocrinol (Lausanne) 2015; 6: 71.
2. Wang GX, Zhao XY, Lin JD. The brown fat secretome: metabolic functions beyond thermogenesis. Trends Endocrinol Metab 2015; 26: 231-7.
3. Gaggini M, Saponaro C, Gastaldelli A. Not all fats are created equal: adipose vs. ectopic fat, implication in cardiometabolic diseases. Horm Mol Biol Clin Investig 2015; 22: 7-18.
4. Rockstroh D, Landgraf K, Wagner IV, et al. Direct evidence of brownadipocytes in different fat depots in children. PLoS One 2015; 10: e0117841.
5. Roman S, Agil A, Peran M, et al. Brown adipose tissue and novel therapeutic approaches to treat metabolic disorders. Transl Res 2015; 165: 464-79.
6. Lovren F, Teoh H, Verma S. Obesity and atherosclerosis: mechanistic insights. Can J Cardiol 2015; 31: 177-83.
7. Rizvi AA, Nikolic D, Sallam HS, Montalto G, Rizzo M, Abate N. Adipokines and lipoproteins: modulation by antihyperglycemic and hypolipidemic agents. Metab Syndr Relat Disord 2014; 12: 1-10.
8. Stepien M, Stepien A, Banach M, et al. New obesity indices and adipokines in normotensive patients and patients with hypertension: comparative pilot analysis. Angiology 2014; 65: 333-42.
9. Bastien M, Poirier P, Lemieux I, Després JP. Overview of epidemiology and contribution of obesity to cardiovascular disease. Prog Cardiovasc Dis 2014; 56: 369-81.
10. Zeng Q, Dong SY, Sun XN, Xie J, Cui Y. Percent body fat is a better predictor of cardiovascular risk factors than body mass index. Braz J Med Biol Res 2012; 45: 591-600.
11. Amato MC, Guarnotta V, Giordano C. Body composition assessment for the definition of cardiometabolic risk. J Endocrinol Invest 2013; 36: 537-43.
12. Lee CM, Huxley RR, Wildman RP, Woodward M. Indices of abdominal obesity arebetter discriminators of cardiovascular risk factors than BMI: a meta-analysis. J Clin Epidemiol 2008; 61: 646-53.
13. Palmer BF, Clegg DJ. The sexual dimorphism of obesity. Mol Cell Endocrinol 2015; 402: 113-9.
14. Bays H. Central obesity as a clinical marker of adiposopathy; increased visceral adiposity as a surrogate marker for global fat dysfunction. Curr Opin Endocrinol Diabetes Obes 2014; 21: 345-51.
15. Tchernof A, Després JP. Pathophysiology of human visceral obesity: an update. Physiol Rev 2013; 93: 359-404.
16. Liu J, Fox CS, Hickson D, et al. Pericardial adipose tissue, atherosclerosis, and cardiovascular disease risk factors: the Jackson heart study. Diabetes Care 2010; 33: 1635-9.
17. Fox CS, Massaro JM, Hoffmann U, et al. Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation 2007; 116: 39-48.
18. Wronska A, Kmiec Z. Structural and biochemical characteristics of various white adipose tissue depots. Acta Physiol (Oxf) 2012; 205: 194-208.
19. Gustafson B, Smith U. Regulation of white adipogenesis and its relation to ectopic fat accumulation and cardiovascular risk. Atherosclerosis 2015; 241: 27-35.
20. Lim S, Meigs JB. Ectopic fat and cardiometabolic and vascular risk. Int J Cardiol 2013; 169: 166-76.
21. Athyros VG, Tziomalos K, Katsiki N, Doumas M, Karagiannis A, Mikhailidis DP. Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update. World J Gastroenterol 2015; 21: 6820-34.
22. Katsiki N, Athyros VG, Karagiannis A, Wierzbicki AS, Mikhailidis DP. Should we expand the concept of coronary heart disease equivalents? Curr Opin Cardiol 2014; 29: 389-95.
23. Lim S, Oh TJ, Koh KK. Mechanistic link between nonalcoholic fatty liver disease and cardiometabolic disorders. Int J Cardiol 2015; 201: 408-14.
24. Rinella ME. Nonalcoholic fatty liver disease: a systematic review. JAMA 2015; 313: 2263-73.
25. Luo J, Xu L, Li J, Zhao S. Nonalcoholic fatty liver disease as a potential risk factor of cardiovascular disease. Eur J Gastroenterol Hepatol 2015; 27: 193-9.
26. Arulanandan A, Ang B, Bettencourt R, et al. Association between quantity of liver fat and cardiovascular risk in patients with nonalcoholic fatty liver diseaseindependent of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2015 Feb3. pii: S1542-3565(15)00113-5.
27. Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol 2015; 62(1Suppl): S47-64.
28. Long MT, Wang N, Larson MG, et al. Nonalcoholic fatty liver disease and vascular function: cross-sectional analysis in the Framingham heartstudy. Arterioscler Thromb Vasc Biol 2015; 35: 1284-91.
29. Osawa K, Miyoshi T, Yamauchi K, et al. Nonalcoholic hepatic steatosis is a strong predictor of high-riskcoronary-artery Plaques as determined by multidetector CT. PLoS One 2015; 10: e0131138.
30. Kwak MS, Yim JY, Kim D, et al. Non-alcoholic fatty liver disease is associated with coronary artery calcium score in diabetes patients with higher HbA1c. Diabetol Metab Syndr 2015; 7: 28.
31. Tison GH, Blaha MJ, Nasir K, et al.Relation of anthropometric obesity and computed tomography measured nonalcoholic fatty liver disease (from the multiethnic study of atherosclerosis). Am J Cardiol 2015 May 21.
32. Abd El-Kader SM, El-Den Ashmawy EM. Non-alcoholic fatty liver disease: Thediagnosis and management. World J Hepatol 2015; 7: 846-58.
33. Zhang QQ, Lu LG. Non-alcoholic Fatty Liver Disease: Dyslipidemia, Risk for cardiovascular complications, and treatment strategy. J Clin Transl Hepatol 2015; 3: 78-84.
34. Li N, Zhang GW, Zhang JR, et al. Non-alcoholic fattyliver disease is associated with progression of arterial stiffness. Nutr Metab Cardiovasc Dis 2015; 25: 218-23.
35. Athyros VG, Katsiki N, Karagiannis A, Mikhailidis DP. Are statins ‘IDEAL’ for non-alcoholic fatty liver disease? Curr Med Res Opin 2014; 30: 229-31.
36. Athyros VG, Katsiki N, Karagiannis A, Mikhailidis DP. Statins and non-alcoholic steatohepatitis. J Hepatol 2015 Oct 8. [Epub ahead of print]
37. Athyros VG, Katsiki N, Karagiannis A, Mikhailidis DP. Statins and non-alcoholic fatty liver disease: a bright future? Expert Opin Investig Drugs 2013; 22: 1089-93.
38. Dongiovanni P, Petta S, Mannisto V, et al. Statin use andnonalcoholic steatohepatitis in at risk individuals. J Hepatol 2015; 63: 705-12.
39. Kargiotis K, Athyros VG, Giouleme O, et al. Resolution of nonalcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome. World J Gastroenterol 2015; 21: 7860-8.
40. Kargiotis K, Katsiki N, Athyros VG, et al. Effect of rosuvastatin on non-alcoholicsteatohepatitis in patients with metabolic syndrome and hypercholesterolaemia: a preliminary report. Curr Vasc Pharmacol 2014; 12: 505-11.
41. Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP. The role of statins in the treatment of type 2 diabetes mellitus: an update. Curr Pharm Des 2014; 20: 3665-74.
42. Tziomalos K, Athyros VG, Paschos P, Karagiannis A. Nonalcoholic fatty liverdisease and statins. Metabolism 2015; 64: 1215-23.
43. Rizos CVD, Liberopoulos EN, Mikhailidis DP, Elisaf MS. Pleiotropic effects ofthiazolidinediones. Expert Opin Pharmacother 2008; 9: 1087-108.
44. Filippatos TD, Derdemezis CS, Gazi IF, Nakou ES, Mikhailidis DP, Elisaf MS.Orlistat-associated adverse effects and drug interactions: a critical review. Drug Saf 2008; 31: 53-65.
45. Lioudaki E, Ganotakis ES, Mikhailidis DP. Ezetimibe; more than a low densitylipoprotein cholesterol lowering drug? An update after 4 years. Curr Vasc Pharmacol 2011; 9: 62-86.
46. Athyros VG, Giouleme O, Ganotakis ES, et al. Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT study. Arch Med Sci 2011; 7: 796-805.
47. Athyros VG, Tziomalos K, Daskalopoulos GN, Karagiannis A, Mikhailidis DP. Statin-based treatment for cardiovascular risk and non-alcoholic fatty liver disease. Killing two birds with one stone? Ann Med 2011; 43: 167-71.
48. Yamada H, Sata M. Role of pericardial fat: The good, the bad and the ugly. J Cardiol 2015; 65: 2-4.
49. Talman AH, Psaltis PJ, Cameron JD, Meredith IT, Seneviratne SK,Wong DT. Epicardial adipose tissue: far more than a fat depot. Cardiovasc Diagn Ther 2014; 4: 416-29.
50. Noyes AM, Dua K, Devadoss R, Chhabra L. Cardiac adipose tissue and its relationship to diabetes mellitus and cardiovascular disease. World J Diabetes 2014; 5: 868-76.
51. Katsiki N, Mikhailidis DP, Wierzbicki AS. Epicardial fat and vascular risk: a narrative review. Curr Opin Cardiol 2013; 28: 458-63.
52. Okada K, Ohshima S, Isobe S, et al. Epicardial fat volume correlates with severity of coronary artery disease in nonobese patients. J Cardiovasc Med (Hagerstown) 2014; 15: 384-90.
53. Iacobellis G, Barbaro G. The double role of epicardial adipose tissue as pro- and anti-inflammatory organ. Horm Metab Res 2008; 40: 442-5.
54. Iacobellis G. Local and systemic effects of the multifaceted epicardialadipose tissue depot. Nat Rev Endocrinol 2015; 11: 363-71.
55. Dey D, Nakazato R, Li D, Berman DS. Epicardial and thoracic fat -Noninvasive measurement and clinical implications. Cardiovasc Diagn Ther 2012; 2: 85-93.
56. Kim BJ, Kim BS, Kang JH. Echocardiographic epicardial fat thickness is associated with coronary artery calcification - results from the CAESAR study. Circ J 2015; 79: 818-24.
57. Bo X, Ma L, Fan J, et al. Epicardial fat volume is correlated with coronary lesion and its severity. Int J Clin Exp Med 2015; 8: 4328-34.
58. Gauss S, Klinghammer L, Steinhoff A, et al. Association of systemic inflammation with epicardial fat and coronary artery calcification. Inflamm Res 2015; 64: 313-9.
59. Lee TH, So MS, Kim BJ, et al. The association between epicardial fat thickness and coronary artery calcification according to blood pressure status in nonhypertensive individuals: From the CAESAR study. J Clin Lipidol 2015; 9: 305-12.
60. Mahabadi AA, Lehmann N, Kälsch H, et al. Association of epicardial adipose tissue with progression of coronary artery calcification is more pronounced in the early phase of atherosclerosis: results from the Heinz Nixdorf recall study. JACC Cardiovasc Imaging 2014; 7: 909-16.
61. Aslanabadi N, Salehi R, Javadrashid A, et al. Epicardial and pericardial fat volume correlate with theseverity of coronary artery stenosis. J Cardiovasc Thorac Res 2014; 6: 235-9.
62. Otaki Y, Hell M, Slomka PJ, et al. Relationship of epicardial fat volume from noncontrast CT with impaired myocardial flow reserve by positron emission tomography. J Cardiovasc ComputTomogr 2015; 9: 303-9.
63. Picard FA, Gueret P, Laissy JP, et al. Epicardial adipose tissue thickness correlates with the presence and severity of angiographic coronary artery diseasein stable patients with chest pain. PLoS One 2014; 9: e110005.
64. Yerramasu A, Dey D, Venuraju S, et al. Increased volume of epicardial fat is an independent risk factor foraccelerated progression of sub-clinical coronary atherosclerosis. Atherosclerosis 2012; 220: 223-30.
65. Tanami Y, Jinzaki M, Kishi S, et al. Lack of association between epicardial fat volume and extent of coronary artery calcification, severity of coronary artery disease, or presence of myocardial perfusion abnormalities in a diverse, symptomatic patient population: results from the CORE320 multi center study. Circ Cardiovasc Imaging 2015; 8: e002676.
66. Mazzali G, Fantin F, Zoico E, et al. Heart fat infiltration in subjects with and without coronary artery disease. J Clin Endocrinol Metab 2015; 100: 3364-71.
67. Mahabadi AA, Berg MH, Lehmann N, et al. Association of epicardial fat with cardiovascular risk factors and incident myocardial infarction in the general population: the Heinz Nixdorf Recall Study. J Am Coll Cardiol 2013; 61: 1388-95.
68. Ito T, Nasu K, Terashima M, et al. The impact of epicardial fat volume on coronary plaque vulnerability: insight from optical coherence tomography analysis. Eur Heart J Cardiovasc Imaging 2012; 13: 408-15.
69. Yamashita K, Yamamoto MH, Ebara S, et al. Association between increased epicardialadipose tissue volume and coronary plaque composition. Heart Vessels 2014; 29: 569-77.
70. Saad Z, El-Rawy M, Donkol RH, Boghattas S. Quantification of epicardial fat: Which method can predict significant coronary artery disease? World J Cardiol 2015; 7: 287-92.
71. Sen F, Yilmaz S, Balci KG, et al. The relationship between epicardial adipose tissue thickness and infarct-related artery patency in patients with st-segment elevation myocardial infarction. Angiology 2015; pii: 0003319715591330.[Epub ahead of print]
72. Bos D, Shahzad R, van Walsum T, et al. Epicardial fat volume is related to atherosclerotic calcification in multiple vessel beds. Eur Heart J Cardiovasc Imag 2015; pii: jev086. [Epub ahead of print]
73. Hartiala O, Magnussen CG, Bucci M, et al. Coronary heart disease riskfactors, coronary artery calcification and epicardial fat volume in the Young Finns Study. Eur Heart J Cardiovasc Imag 2015 Apr 20. pii: jev085. [Epub ahead of print]
74. Rabkin SW. The relationship between epicardial fat and indices of obesity andthe metabolic syndrome: a systematic review and metaanalysis. Metab Syndr Relat Disord 2014; 12: 31-42.
75. Shim IK, Cho KI, Kim HS, Heo JH, Cha TJ. Impact of gender on the association of epicardial fat thickness, obesity, and circadian blood pressure pattern in hypertensive patients. J Diabetes Res 2015; 2015: 924539.
76. Baldasseroni S, Pratesi A, Orso F, et al. Epicardial adipose tissueand insulin resistance in patients with coronary artery disease with or without left ventricular dysfunction. Monaldi Arch Chest Dis 2013; 80: 170-6.
77. Bertaso AG, Bertol D, Duncan BB, Foppa M. Epicardial fat: definition, Measurements and systematic review of main outcomes. Arq Bras Cardiol 2013; 101: e18-28.
78. Fitzgibbons TP, Czech MP. Epicardial and perivascular adipose tissues and their influence on cardiovascular disease: basic mechanisms and clinical associations. J Am Heart Assoc 2014; 3: e000582.
79. Song Do K, Hong YS, Lee H, Oh JY, Sung YA, Kim Y. Increased epicardial adipose tissue thickness in type 2 diabetes mellitus and obesity. Diabetes Metab J 2015; 39: 405-13.
80. Aslan AN, Keleş T, Ayhan H, et al. The relationship between epicardial fat thickness and endothelial dysfunction in type i diabetes mellitus. Echocardiography 2015 Apr 27. doi: 10.1111/echo.12960. [Epub ahead of print]
81. Mahfouz RA, Alzaiat A, Yousry A. Relationship of epicardial fat thickness with endothelial and cardiac functions in children with family history of type 2 diabetes mellitus. Echocardiography 2015; 32: 28-33.
82. Akbas EM, Hamur H, Demirtas L, et al. Predictors of epicardial adipose tissue in patients with type 2 diabetes mellitus. Diabetol-Metab Syndr 2014; 6: 55.
83. Akboga MK, Canpolat U, Yayla C, et al. Association of platelet to lymphocyte ratio with inflammation and severity of coronary atherosclerosis in patients with stable coronary artery disease. Angiology 2016; 67: 89-95.
84. Ozcan Cetin EH, Cetin MS, Aras D, et al. Platelet to lymphocyte ratio as a prognostic marker of in-hospital and long-term major adverse cardiovascular events in st-segment elevation myocardial infarction. Angiology 2015 Jun 22. pii: 0003319715591751. [Epub ahead of print]
85. Verdoia M, Barbieri L, Di Giovine G, Marino P, Suryapranata H, De Luca G; Novara Atherosclerosis Study Group (NAS). Neutrophil to lymphocyte ratio and the extent of coronary artery disease: Results from a large cohort study. Angiology 2016; 67: 75-82.
86. Cho KI, Ann SH, Singh GB, Her AY, Shin ES. Combined usefulness of the platelet-to-lymphocyte ratio and the neutrophil-tolymphocyte ratio in predicting the long-term adverse events in patients who have undergone percutaneous coronary intervention with a drug-eluting stent. PLoS One 2015; 10: e0133934.
87. Akil E, Akil MA, Varol S, et al. Echocardiographic epicardial fat thickness and neutrophil to lymphocyte ratio are novel inflammatory predictors of cerebral ischemic stroke. J Stroke Cerebrovasc Dis 2014; 23: 2328-34.
88. Nar G, Inci S, Aksan G, Unal OK, Nar R, Soylu K. The relationship between epicardial fat thickness and gestational diabetes mellitus. Diabetol Metab Syndr 2014; 6: 120.
89. Fernández Muñoz MJ, Basurto Acevedo L, Córdova Pérez N, et al. Epicardialadipose tissue is associated with visceral fat, metabolic syndrome, and insulin resistance in menopausal women. Rev Esp-Cardiol (Engl Ed) 2014; 67: 436-41.
90. Balci A, Celik M, Balci DD, et al. Patients with psoriasis have an increased amount of epicardial fattissue. Clin Exp Dermatol 2014; 39: 123-8.
91. Muniyappa R, Noureldin R, Ouwerkerk R, et al. Myocardial fat accumulation is independent of measures of insulin sensitivity. J Clin Endocrinol Metab 2015 May 28: jc20151139.[Epub ahead of print]
92. Petta S, Argano C, Colomba D, et al. Epicardial fat, cardiac geometry andcardiac function in patients with non-alcoholic fatty liver disease: association with the severity of liver disease. J Hepatol 2015; 62: 928-33.
93. Natale F, Tedesco MA, Mocerino R, et al. Visceral adiposityand arterial stiffness: echocardiographic epicardial fat thickness reflects, better than waist circumference, carotid arterial stiffness in a large populationof hypertensives. Eur J Echocardiogr 2009; 10: 549-55.
94. Kocaman SA, Durakoğlugil ME, Çetin M, Erdoğan T, Ergül E, Çanga A. The independent relationship of epicardial adipose tissue with carotidintima-media thickness and endothelial functions: the association of pulse wave velocity with the active facilitated arterial conduction concept. Blood Press Monit 2013; 18: 85-93.
95. Colak Y, Karabay CY, Tuncer I, et al. Relation of epicardial adipose tissue and carotid intima-media thickness in patients with nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 2012; 24: 613-8.
96. Nelson MR, Mookadam F, Thota V, et al. Epicardial fat: an additional measurement for sub clinical atherosclerosis and cardiovascular risk stratification? J Am Soc Echocardiogr 2011; 24: 339-45.
97. Unubol M, Eryilmaz U, Guney E, Akgullu C, Kurt Omurlu I. Epicardial adipose tissue in patients with subclinical hypothyroidism. Minerva Endocrinol 2014; 39: 135-40.
98. Lioudaki E, Mavroeidi NG, Mikhailidis DP, Ganotakis ES. Subclinical hypothyroidism and vascular risk: an update. Hormones (Athens) 2013; 12: 495-506.
99. Sunbul M, Agirbasli M, Durmus E, et al. Arterial stiffness in patients with non-alcoholic fatty liver disease is related to fibrosis stage and epicardial adipose tissue thickness. Atherosclerosis 2014; 237: 490-3.
100. Korkmaz L, Cirakoglu OF, Ağaç MT, et al. Relation of epicardial adipose tissue with arterial compliance and stiffness in patients with hypertension. Angiology 2014; 65: 691-5.
101. Hachiya K, Fukuta H, Wakami K, Goto T, Tani T, Ohte N. Relation of epicardial fat to central aortic pressure and left ventricular diastolic function in patients with known or suspected coronary artery disease. Int J Cardiovasc Imag 2014; 30: 1393-8.
102. Cabrera-Rego JO, Iacobellis G, Castillo-Herrera JA, et al. Epicardial fat thickness correlates with carotid intima-media thickness, arterial stiffness, and cardiac geometry in children and adolescents. Pediatr Cardiol 2014; 35: 450-6.
103. Hatem SN, Sanders P. Epicardial adipose tissue and atrial fibrillation. Cardiovasc Res 2014; 102: 205-13.
104. Cordeiro AC, Amparo FC, Oliveira MA, et al. Epicardial fat accumulation, cardiometabolic profile and cardiovascular events in patients with stages 3-5 chronic kidney disease. J Intern Med 2015; 278: 77-87.
105. Kaplan O, Kurtoglu E, Gozubuyuk G, et al. Epicardial adipose tissue thickness in patients with chronic obstructive pulmonary disease having right ventricular systolic dysfunction. Eur Rev Med Pharmacol Sci 2015; 19: 2461-7.
106. Gaisl T, Schlatzer C, Schwarz EI, et al. Coronary artery calcification, epicardial fat burden, and cardiovascular events in chronic obstructive pulmonary disease. PLoS One 2015; 10: e0126613.
107. Ong KL, Ding J, McClelland RL, et al. Relationship of pericardial fat with lipoprotein distribution: The Multi-Ethnic study of atherosclerosis. Atherosclerosis 2015; 241: 664-70.
108. Ong KL, Ding J, McClelland RL, et al. Relationship of pericardial fat with biomarkers of inflammation and hemostasis, and cardiovascular disease: the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis 2015; 239: 386-92.
109. Wu CK, Tsai HY, Su MY, et al. Pericardial fat is associated with ventricular tachyarrhythmia and mortality in patients with systolic heart failure. Atherosclerosis 2015; 241: 607-14.
110. Al-Rawahi M, Proietti R, Thanassoulis G. Pericardial fat and atrial fibrillation: Epidemiology, mechanisms and interventions. Int J Cardiol 2015; 195: 98-103.
111. Brinkley TE, Hsu FC, Carr JJ, et al. Pericardial fat is associated with carotid stiffness in the Multi-Ethnic Study of Atherosclerosis. Nutr Metab Cardiovasc Dis 2011; 21: 332-8.
112. Bosy-Westphal A, Kossel E, Goele K, et al. Association of pericardial fat with liver fat and insulin sensitivity after diet-induced weight loss in overweight women. Obesity (Silver Spring) 2010; 18: 2111-7.
113. Larsen BA, Laughlin GA, Saad SD, Barrett-Connor E, Allison MA, Wassel CL. Pericardial fat is associated with all-cause mortality but not incident CVD: The rancho bernardo study. Atherosclerosis 2015; 239: 470-5.
114. Sicari R, Sironi AM, Petz R, et al. Pericardial rather than epicardial fat is a cardio metabolic risk marker: an MRI vs echo study. J Am Soc Echocardiogr 2011; 24: 1156-62.
115. Soliman EZ, Ding J, Hsu FC, Carr JJ, Polak JF, Goff DC Jr. Association between carotid intima-media thickness and pericardial fat in the Multi-Ethnic Study of Atherosclerosis (MESA). J Stroke Cerebrovasc Dis 2010; 19: 58-65.
116. Snel M, Jonker JT, Hammer S, et al. Long-term beneficial effect of a 16-week very low calorie diet on pericardial fat in obese type 2 diabetes mellitus patients. Obesity (Silver Spring) 2012; 20: 1572-6.
117. Iacobellis G, SinghN, WhartonS, Sharma AM. Substantial changes in epicardial fat thickness after weight loss in severely obese subjects. Obesity (Silver Spring) 2008; 16: 1693-7.
118. Kim MK, Tomita T, Kim MJ, Sasai H, Maeda S, Tanaka K. Aerobic exercise training reduces epicardial fat in obese men. J Appl Physiol 2009; 106: 5-11.
119. Park JH, Park YS, Kim YJ, et al. Effects of statins on the epicardial fat thickness in patients with coronary artery stenosis underwent percutaneous coronary intervention: comparison of atorvastatin with simvastatin/ezetimibe. J Cardiovasc Ultrasound 2010; 18: 121-6.
120. Takase H, Dohi Y, Okado T, Hashimoto T, Goto Y, Kimura G. Effects of ezetimibe on visceral fat in the metabolic syndrome: a randomised controlled study. Eur J Clin Invest 2012; 42: 1287-94.
121. Morano S, Romagnoli E, Filardi T, et al. Short-term effects of glucagon-like peptide 1 (GLP-1) receptor agonists on fat distribu tion in patients with type 2diabetes mellitus: an ultrasonography study. Acta Diabetol 2015 Jan 11. [Epub ahead of print]
122. Lima-Martínez MM, Paoli M, Rodney M, Balladares N, Contreras M, D’Marco L, Iacobellis G. Effect of sitagliptin on epicardial fat thickness in subjects with type 2 diabetes and obesity: a pilot study. Endocrine 2015 Aug 2. [Epub ahead of print]
123. Elisha B, Azar M, Taleb N, Bernard S, Iacobellis G, Rabasa-Lhoret R. Body composition and epicardial fat in type 2 diabetes patients following insulin detemir versus insulin glargine initiation. Horm Metab Res 2015 Sep 4. [Epub ahead of print]
124. van Schinkel LD, Sleddering MA, Lips MA, et al. Effects of bariatric surgery on pericardial ectopic fat depositions and cardiovascular function. Clin Endocrinol (Oxf) 2014; 81: 689-95.
125. Vasques AC, Pareja JC, Souza JR, et al. Epicardial and pericardial fat in type 2 diabetes: favourable effects of biliopancreatic diversion. Obes Surg 2015; 25: 477-85.
126. Grosso AF, de Oliveira SF, Higuchi Mde L, Favarato D, Dallan LA, da Luz PL. Synergistic anti-inflammatory effect: simvastatin and pioglitazone reduce inflammatory markers of plasma and epicardial adipose tissue of coronary patients with metabolic syndrome. Diabetol Metab Syndr 2014; 6: 47.
127. Jonker JT, Lamb HJ, van der Meer RW, et al. Pioglitazone compared with metformin increases pericardial fat volume in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2010; 95: 456-60.
128. Kitterer D, Latus J, Henes J, et al. Impact of long-term steroid therapy on epicardial and pericardial fat deposition: a cardiac MRI study. Cardiovasc Diabetol 2015; 14: 130.
129. Lastra G, Manrique C. Perivascular adipose tissue, inflammation and insulin resistance: link to vascular dysfunction and cardiovascular disease. Horm Mol Biol Clin Investig 2015; 22: 19-26.
130. Haberka M, Gąsior Z. Carotid extra-media thickness in obesity and metabolicsyndrome: a novel index of perivascular adipose tissue: extra-media thickness in obesity and metabolic syndrome. Atherosclerosis 2015; 239: 169-77.
131. Britton KA, Pedley A, Massaro JM, Corsini EM, Murabito JM, Hoffmann U, Fox CS. Prevalence, distribution, and risk factor correlates of high thoracic periaortic fat in the Framingham Heart Study. J Am Heart Assoc. 2012; 1: e004200.
132. Rittig K, Dolderer JH, Balletshofer B, et al. The secretion pattern of perivascular fat cells is different from that of subcutaneous and visceral fat cells. Diabetologia 2012; 55: 1514-25.
133. Villacorta L, Chang L. The role of perivascular adipose tissue in vasoconstriction, arterial stiffness, and aneurysm. Horm Mol Biol Clin Investig 2015; 21: 137-47.
134. Omar A, Chatterjee TK, Tang Y, Hui DY, Weintraub NL. Proinflammatoryphenotype of perivascular adipocytes. Arterioscler-Thromb Vasc Biol 2014; 34: 1631-6.
135. Achike FI, To NH, Wang H, Kwan CY. Obesity, metabolic syndrome, adipocytes and vascular function: A holistic viewpoint. Clin Exp Pharmacol Physiol 2011; 38: 1-10.
136. Gil-Ortega M, Condezo-Hoyos L, García-Prieto CF, et al. Imbalance between pro- and anti-oxidant mechanisms in perivascular adipose tissue aggravates long-term high-fat diet-derived endothelial dysfunction. PLoS One 2014; 9: e95312.
137. Chang L, Milton H, Eitzman DT, Chen YE. Paradoxical roles of perivascular adipose tissue in atherosclerosis and hypertension. Circ J 2013; 77: 11-8.
138. Aroor AR, Demarco VG, Jia G, et al. The role of tissue Renin-Angiotensin-aldosterone system in the development of endothelial dysfunction and arterial stiffness. Front Endocrinol (Lausanne) 2013; 4: 161.
139. Chatterjee TK, Aronow BJ, Tong WS, et al. Human coronary artery perivascular adipocytes overexpress genes responsible for regulating vascular morphology, inflammation, and hemostasis. Physiol Genomics 2013; 45: 697-709.
140. Lehman SJ, Massaro JM, Schlett CL, et al. Peri-aortic fat, cardiovascular disease risk factors, and aortic calcification: The framingham heart study. Atherosclerosis 2010; 210: 656-61.
141. Britton KA, Wang N, Palmisano J, et al. Thoracicperiaortic and visceral adipose tissue and their cross-sectional associations with measures of vascular function. Obesity (Silver Spring) 2013; 21: 1496-503.
142. Shields KJ, Barinas-Mitchell E, Gingo MR, et al. Perivascular adipose tissue of the descending thoracicaorta is associated with systemic lupus erythematosus and vascular calcification in women. Atherosclerosis 2013; 231: 129-35.
143. Longenecker CT, Jiang Y, Yun CH, et al. Perivascular fat, inflammation, and cardiovascular risk in HIV-infected patients on antiretroviral therapy. Int J Cardiol 2013; 168: 4039-45.
144. Mazurek T, Opolski G. Pericoronary adipose tissue: a novel therapeutic targetin obesity-related coronary atherosclerosis. J Am Coll Nutr 2015; 34: 244-54.
145. Maurovich-Horvat P, Kallianos K, Engel LC, et al. Relationship of thoracic fat depots with coronary atherosclerosis and circulating inflammatory biomarkers. Obesity (Silver Spring) 2015; 23: 1178-84.
146. Demircelik MB, Yilmaz OC, Gurel OM, et al. Epicardial adipose tissue and pericoronary fat thickness measured with 64-multidetector computed tomography: potential predictors of the severity of coronary artery disease. Clinics (Sao Paulo) 2014; 69: 388-92.
147. Mahabadi AA, Reinsch N, Lehmann N, et al. Association of pericoronary fat volume with atherosclerotic plaque burden in the underlying coronary artery: a segment analysis. Atherosclerosis 2010; 211: 195-9.
148. Almabrouk TA, Ewart MA, Salt IP, Kennedy S. Perivascular fat, AMP-activated protein kinase and vascular diseases. Br J Pharmacol 2014; 171: 595-617.
149. Ewart MA, Kennedy S. AMPK and vasculo protection. Pharmacol Ther 2011; 131: 242-53.
150. Wang X, Lin Y, Luo N, et al. Short-term intensive atorvastatin therapy improves endothelial function partly via attenuating perivascular adipose tissue inflammation through 5-lipoxygenase pathway in hyperlipidemic rabbits. Chin Med J (Engl) 2014; 127: 2953-9.
151. Aghamohammadzadeh R, Greenstein AS, Yadav R, et al. Effects of bariatric surgery on human small artery function: evidence for reduction in perivascular adipocyte inflammation, and the restoration of normal anticontractile activity despite persistent obesity. J Am Coll Cardiol 2013; 62: 128-35.
152. Schrauwen-Hinderling VB, Hesselink MKC, Schrauwen P, Kooi ME. Intramyo cellular lipid content in human skeletal muscle. Obesity 2006; 14: 357-67.
153. Lim S. Ectopic fat assessment focusing on cardio metabolic and renal risk. Endocrinol Metab (Seoul) 2014; 29: 1-4.
154. Pietiläinen KH, Kaye S, Karmi A, Suojanen L, Rissanen A, Virtanen KA. Agreement of bioelectrical impedance with dual-energy X-ray absorptiometry and MRI to estimate changes in body fat, skeletal muscle and visceral fat during a12-month weight loss intervention. Br J Nutr 2013; 109: 1910-6.
155. Andreoli A, Scalzo G, Masala S, Tarantino U, Guglielmi G. Body composition assessment by dual-energy X-ray absorptiometry (DXA). Radiol Med 2009; 114: 286-300.
156. Hasegawa N, Kurihara T, Sato K, et al. Intramyocellular and extramyocellular lipids are associated with arterial stiffness. Am J Hypertens 2015 Apr 24.pii: hpv041. [Epub ahead ofprint]
157. Velan SS, Said N, Durst C, et al. Distinct patterns of fat metabolism inskeletal muscle of normal-weight, overweight, and obese humans. Am J Physiol Regul Integr Comp Physiol 2008; 295: R1060-5.
158. de la Maza MP, Hirsch S, Jara N, et al. Central obesity and not age increases skeletal muscle lipids, without influencing lean body mass and strength. Nutr Hosp 2014; 31: 1134-41.
159. Fonvig CE, Bille DS, Chabanova E, Nielsen TR, Thomsen HS, Holm JC. Muscle fat content and abdominal adipose tissue distribution investigated by magnetic resonance spectroscopy and imaging in obese children and youths. Pediatr Rep 2012; 4: e11
160. Stump CS, Henriksen EJ, Wei Y, Sowers JR. The metabolic syndrome: role of skeletal muscle metabolism. Ann Med 2006; 38: 389-402.
161. Therkelsen KE, Pedley A, Speliotes EK, et al. Intramuscular fat and associations with metabolic risk factors in the Framingham Heart Study. Arterioscler Thromb Vasc Biol 2013; 33: 863-70.
162. Moon MK, Hong ES, Lim JA, et al. Associations between thyroid hormone levels and regional fat accumulation in euthyroid men. Eur J Endocrinol 2013; 168: 805-10.
163. Miljkovic I, Kuipers AL, Cauley JA, et al; Osteoporotic fractures in men study group. Greater skeletal muscle fat infiltration is associated with higher all-cause and cardiovascular mortality in older men. J Gerontol A BiolSci Med Sci 2015; 70: 1133-40.
164. Godoy-Matos AF, Bahia LR, Domingues RC, et al. Rosiglitazone decreases intra- to extramyocellularfat ratio in obese non-diabetic adults with metabolic syndrome. Diabet Med 2010; 27: 23-9.
165. Chabowski A, Zendzian-Piotrowska M, Nawrocki A, Górski J. Not only accumulation, but also saturation status of intramuscular lipids is significantly affected by PPAR_ activation. Acta Physiol (Oxf) 2012; 205: 145-58.
166. Pouwels KB, van Grootheest K. The rosiglitazone decision process at FDA and EMA. What should we learn? Int J Risk Saf Med 2012; 24: 73-80.
167. Defronzo RA, Mehta RJ, Schnure JJ. Pleiotropic effects of thiazolidinediones: implications for the treatment of patients with type 2 diabetes mellitus. Hosp Pract (1995) 2013; 41: 132-47.
168. Bajaj M, Baig R, Suraamornkul S, et al. Effects of pioglitazone on intramyocellular fat metabolism in patients with type 2 diabetes mellitus. Clin Endocrinol Metab 2010; 95: 1916-23.
169. Teranishi T, Ohara T, Maeda K, et al. Effects of pioglitazone and metformin on intracellular lipid content in liver and skeletal muscle of individuals with type 2 diabetes mellitus. Metabolism 2007; 56: 1418-24.
170. Wang C, Liu F, Yuan Y, et al.Metformin suppresses lipid accumulation in skeletal muscle by promoting fatty acid oxidation. Clin Lab 2014; 60: 887-96.
171. Dandona P, Rosenberg MT. A practical guide to male hypogonadism in the primarycare setting. Int J Clin Pract 2010; 64: 682-96.
172. Martin DR, Karabulut N, Yang M, McFadden DW. High signal peripancreatic fat on fat-suppressed spoiled gradient echo imaging in acute pancreatitis: preliminary evaluation of the prognostic significance. J Magn Reson Imaging 2003; 18: 49-58.
173. Yashima Y, Isayama H, Tsujino T, et al. A large volume of visceral adipose tissue leads to severe acute pancreatitis. J Gastroenterol 2011; 46: 1213-8.
174. Schäffler A, Landfried K, Völk M, et al. Potential of adipocytokines in predicting peripancreatic necrosis and severityin acute pancreatitis: pilot study. J Gastroenterol Hepatol 2007; 22: 326-34.
175. Jamieson NB, Foulis AK, Oien KA, et al.Peripancreatic fat invasion is an independent predictor of poor outcome following pancreaticoduodenectomy for pancreatic ductal adenocarcinoma. J Gastrointest Surg 2011; 15: 512-24.
176. Macauley M, Percival K, Thelwall PE, Hollingsworth KG, Taylor R. Altered volume, morphology and composition of the pancreas in type 2 diabetes. PLoS One 2015; 10: e0126825.
177. Lim S, Meigs JB. Links between ectopic fat and vascular disease in humans. Arterioscler Thromb Vasc Biol 2014; 34: 1820-6.
178. Begovatz P, Koliaki C, Weber K, et al. Pancreatic adipose tissue infiltration, parenchymal steatosis and beta cell function in humans. Diabetologia 2015 Mar 5. [Epub ahead of print]
179. Uygun A, Kadayifci A, Demirci H, et al. The effect of fatty pancreas on serum glucose parameters in patients with nonalcoholic steatohepatitis. Eur J Intern Med 2015; 26: 37-41.
180. Kawasaki S, Hasegawa O, Satoh S, Numata K, Terauchi Y. Sonographic assessment of fatty liver infiltration using the measurement of para- and perirenal fatthickness. J Clin Ultrasound 2010; 38: 470-4.
181. Tsili AC, Goussia AC, Baltogiannis D, et al. Perirenal fat invasion on renal cell carcinoma: evaluation with multidetector computed tomography-multivariate analysis. J Comput Assist Tomogr 2013; 37: 450-7.
182. Eisner BH, Zargooshi J, Berger AD, et al. Gender differences in subcutaneous and perirenal fat distribution. Surg Radiol Anat 2010; 32: 879-82.
183. Anderson KM, Lindler TU, Lamberton GR, Baron PW, Ojogho OK, Baldwin DD. Laparoscopic donor nephrectomy: effect of perirenal fat upon donor operative time. J Endourol 2008; 22: 2269-74.
184. Jung M, Volonté F, Buchs NC, et al. Perirenal fat surface area as a risk factor for morbidity after electivecolorectal surgery. Dis Colon Rectum 2014; 57: 201-9.
185. Sun X, Han F, Miao W, Hou N, Cao Z, Zhang G. Sonographic evaluation of para-and perirenal fat thickness is an independent predictor of early kidney damage inobese patients. Int Urol Nephrol 2013; 45: 1589-95.
186. Lamacchia O, Nicastro V, Camarchio D, et al. Para- and perirenal fat thickness is an independent predictor ofchronic kidney disease, increased renal resistance index and hyperuricaemia intype-2 diabetic patients. Nephrol Dial Transplant 2011; 26: 892-8.
187. Grima P, Guido M, Zizza A, Chiavaroli R. Sonographically measured perirenalfat thickness: an early predictor of atherosclerosis in HIV-1-infected patientsreceiving highly active antiretroviral therapy? J Clin Ultrasound 2010; 38: 190-5.
188. Khene ZE, Peyronnet B, Mathieu R, Fardoun T, Verhoest G, Bensalah K. Analysis of the impact of adherent perirenal fat on perioperative outcomes of robotic partial nephrectomy. World J Urol 2015 Feb 11. [Epub ahead of print]
189. Wang Y, Song Y, Suo M, Jin X, Tian G. Telmisartan prevents high-fat diet-induced hypertension and decreases perirenal fat in rats. J Biomed Res 2012; 26: 219-25.
190. Li Z, Woollard JR, Wang S, et al. Increased glomerular filtration rate in early metabolic syndrome is associated with renal adiposity and microvascular proliferation. Am J Physiol Renal Physiol 2011; 301: F1078-87.
191. Roever L, Resende ES, Veloso FC, et al. Perirenal fat and association with metabolic risk factors: The uberlândia heart study. Medicine (Baltimore) 2015; 94: e1105.
192. Nagano G, Ohno H, Oki K, et al. Activation of classical brown adipocytes in the adult human perirenal depot is highlycorrelated with PRDM16-EHMT1 complex expression. PLoS One 2015; 10: e0122584.